Unlocking a New Era: Illumina’s 5-Base Solution Bridges Genomics and Epigenomics for Multiomic Discovery

Illumina, Inc. has unveiled its groundbreaking 5-base solution, setting a new standard for multiomic research by enabling scientists to simultaneously analyze genomic and epigenomic information from a single sample. According…

Continue Reading Unlocking a New Era: Illumina’s 5-Base Solution Bridges Genomics and Epigenomics for Multiomic Discovery

Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases

Merck has announced a significant expansion of its clinical development program for tulisokibart (MK-7240), an investigational monoclonal antibody targeting the inflammatory mediator TL1A. Reported by Drugs.com, in October 2025, the…

Continue Reading Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases

Genetic Risk for Dilated Cardiomyopathy May Elevate Vulnerability to Secondary Cardiomyopathies

Emerging research highlights the role of genetic predisposition in the development of secondary cardiomyopathies triggered by environmental stressors such as pregnancy, alcohol use, and cancer therapy. Findings published in JAMA…

Continue Reading Genetic Risk for Dilated Cardiomyopathy May Elevate Vulnerability to Secondary Cardiomyopathies

Alera Bio Takes Bold Step Toward First Treatment for MCT-8 Deficiency with AB-101 Program

Alera Bio, a Chicago-based biotech company dedicated to rare neurological diseases, has announced a significant breakthrough in the quest to treat MCT-8 deficiency, otherwise known as Allan-Herndon-Dudley Syndrome. On September…

Continue Reading Alera Bio Takes Bold Step Toward First Treatment for MCT-8 Deficiency with AB-101 Program

JCR Pharmaceuticals and Alexion Mark Key Progress in Neurodegenerative Disease Collaboration

JCR Pharmaceuticals Co., Ltd., a leader in therapies for rare and genetic diseases, has reached an important milestone in its ongoing collaboration with Alexion, AstraZeneca’s rare disease division. The achievement,…

Continue Reading JCR Pharmaceuticals and Alexion Mark Key Progress in Neurodegenerative Disease Collaboration

Cracking the Code: Mayo Clinic Hosts First U.S. “Undiagnosed Hackathon” to Solve Rare Medical Mysteries

On Sunday, more than 100 medical experts from across the globe gathered in Rochester for the Mayo Clinic’s four-day “Undiagnosed Hackathon”—a pioneering event dedicated to solving rare diseases that have…

Continue Reading Cracking the Code: Mayo Clinic Hosts First U.S. “Undiagnosed Hackathon” to Solve Rare Medical Mysteries